# US 2010/0166740 A1 · Anti-OX40L antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166740 A1
- Document ID: US20100166740A1
- Status: Published application
- Kind: A1
- Application number: 12/315,863
- Filed: 2008-12-05
- Published: 2010-07-01
- Earliest claimed: 2004-09-17
- Assignees: Roche Palo Alto LLC
- Inventors: Joseph Endl; Elsie M. Eugui; Maria Elena Fuentes; Yvo Graus; Aran Frank Labrijn; Martin Lanzendoerfer; Paul Parren; Frank Rebers; Ralf Schumacher; Stefan Seeber; Jan Van de Winkel; Martine Van Vugt
- Web page: https://patentgrep.com/patent/US20100166740A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

## Claims

### Claim 1

An antibody, characterized in that said antibody binds OX40L, contains a Fc part derived from human origin, the light chain variable domain defined by amino acid sequence SEQ ID NO:1 and the heavy chain variable domain defined by SEQ ID NO:2, and does not bind complement factor C1q.

### Claim 2 (depends on 1)

The antibody according to claim 1, characterized in that the antibody does not bind to human Fcγ receptors on NK cells.

### Claim 3 (depends on 2)

The antibody according to claim 2, characterized in that the antibody is a human antibody.

### Claim 4 (depends on 2)

The antibody according to claim 2, characterized in that the antibody is a chimeric or humanized antibody.

### Claim 5 (depends on 1)

The antibody according to claim 1, wherein the antibody binds to OX40L with a KD value of less than 10−8 M.

### Claim 6 (depends on 5)

The antibody according to claim 5, wherein the KD range is between about 10−12 to about 10−9 M.

### Claim 7 (depends on 6)

The antibody according to claim 6, characterized in that the antibody is an antibody of human subclass IgG1, containing one or more mutations selected from PVA236, GLPSS331 and/or L234A/L235A (numbering according to EU index).

### Claim 8 (depends on 6)

The antibody according to claim 6, characterized in that the antibody is an antibody of human subclass IgG4.

### Claim 9 (depends on 8)

The antibody according to claim 8, characterized in containing mutation S228P.

### Claim 10 (depends on 8)

The antibody according to claim 8, characterized in containing mutation L235E.

### Claim 11 (depends on 1)

The antibody according to claim 1, characterized in that does not activate complement factor C3.

### Claim 12 (depends on 1)

The antibody according to claim 1, characterized in that it does not elicit complement-dependent cytotoxicity (CDC).

### Claim 13 (depends on 1)

The antibody according to claim 1, characterized in that it does not elicit antibody-dependent cellular cytotoxicity (ADCC).

### Claim 14 (depends on 1)

The antibody according to claim 1, characterized in that it shows in an ELISA assay inhibition by blocking the interaction of immobilized OX40L with soluble OX40 at a coating concentration of 0.5 μg/ml OX40L with an IC50 value in the range of 1 nM-4 nM.

### Claim 15

An antibody, characterized in that said antibody binds OX40L and that the antibody comprises a variable region combination including the light chain variable domain defined by amino acid sequence SEQ ID NO:1 and the heavy chain variable domain defined by SEQ ID NO:2.

### Claim at position 16

16-18. (canceled)

### Claim 19 (depends on 1)

The antibody according to claim 1, characterized in that the antibody comprises at least one amino acid mutation in the Fc part causing non-binding to complement factor C1q.

### Claim 20 (depends on 19)

The antibody according to claim 19, characterized in that the antibody comprises a kappa light chain constant region as defined by SEQ ID NO:13.

### Claim 21 (depends on 20)

The antibody according to claim 20, characterized in that the antibody comprises a constant region as defined by SEQ ID NO:14 or SEQ ID NO:15.

### Claim at position 20

22-23. (canceled)

### Claim 24

An antibody, characterized in that it is produced by the cell line
hu-Mab<hOX40L>LC.001.

### Claim 25 (depends on 1)

The antibody according to claim 1 characterized in that the antibody is a Fab, F(ab′)2 or a single-chain fragment.

### Claim at position 23

26-31. (canceled)

### Claim 32 (depends on 1)

A composition comprising an antibody molecule of claim 1 or an antibody molecule produced by the method comprising:
a) providing a host cell comprising an expression vector which comprises a modified first nucleic acid and a second nucleic acid encoding the light chain of said antibody;
b) culturing said host cell under conditions that allow synthesis of said antibody; and
c) recovering said antibody from said host cell,
wherein the sequence of said first nucleic acid encoding the heavy chain of said antibody encodes the heavy chain of an antibody according to claim 1, wherein said antibody is characterized in that the antibody binds to OX40L with a KD value of less than 10−8 M and is modified in such a manner that said modified antibody does not bind complement factor C1q and/or human Fcγ receptor on NK cells.

### Claim 33 (depends on 32)

The composition of claim 32, further comprising a pharmaceutically acceptable excipient.

### Claim 34 (depends on 1)

A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable excipient.

### Claim at position 27

35-38. (canceled)
